TB,some help in identifying the...

TB,

some help in identifying the differences....

corporatefile.com.au:

Bayer has recently filed an NDA for Nexavar for advanced primary liver cancer in
the U.S. What are the differences between PI-88 and Nexavar?

CEO Justus Homburg:

PI-88 and Nexavar are both being developed for primary liver cancer, but for
different segments of the patient population. Onyx and Bayer have released
survival data from the Phase 3 SHARP study detailing Nexavar’s utility for
patients with advanced primary liver cancer that are not candidates for surgery and
Progen is developing PI-88 as an additional treatment to resection amongst liver
cancer patients who are amenable to surgery.
Both are angiogenesis inhibitors, but they work very differently (different mode of
action) and may therefore have the potential to be used in combination or
sequentially for the treatment of, amongst others, primary liver cancer patients
who have had surgery or are no longer candidates for tumour resection. Both
drugs function in broad terms as angiogenesis inhibitors and so we view the recent
Nexavar data and NDA as a powerful validation for the development of PI-88 in
this broad indication.